Recently, Compuware Corporation declared that its Project Portfolio Management (PPM) solution, Changepoint, has been adopted by St. John New Zealand.
The reason behind selecting Compuware’s platform is its highly developed technology along with flexible, scalable and integrated systems.
St. John is engaged in providing a wide range of health-related services to various communities across New Zealand. This association with Compuware will help this organization deploy the company’s Software-as-a Service (Saas) solution through utilizing the Changepoint platform.
The company through its PPM solution will be offering an in-depth knowledge of projects, investments and resources. In addition, this platform will also provide various applications including better business planning and advanced decision-making procedure.
Management averred that its completely integrated user-friendly solution would improve the businesses of St. John through properly managing its range of operations. St. John would also benefit immensely from this association through augmenting its operations significantly.
Compuware’s key objective is to provide most user-friendly, technologically advanced services to its clients in IT organizations through its improved software as a service (SaaS), professional and application services platform.
Compuware operates in an intensely competitive landscape. In the software business, the company is always under pressure for innovating new products to attract new clients and also maintain the existing associations which may prove to be expensive. According to management, the company competes with more than 40 firms in one or more of its offerings. Rivals include BMC Software Inc. , CA Technologies , International Business Machines Corporation .
The current Zacks Consensus Estimates for the second quarter of fiscal 2013 and for fiscal 2013 are 6 cents per share and 43 cents per share, respectively. The company currently retains a Zacks #3 Rank, which translates into a short-term ‘Hold’ rating. We also have a ‘Neutral’ recommendation on the company’s stock.